SANA

Sana Biotechnology (SANA)

Sana Biotechnology Inc

일자:

규정 관련뉴스

텍스트 검색:

정렬 기준:

규정 외 뉴스

검색 관련기사 보기:NASDAQ:SANA

1 2 3 4 5 6 7 8 다음 >>

일자	시간	출처	헤드라인	심볼	기업
2025/03/18	05:37	Edgar (US Regulatory)	Form POS AM - Post-Effective amendments for registration statement	NASDAQ:SANA	Sana Biotechnology Inc
2025/03/18	05:12	Edgar (US Regulatory)	Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]	NASDAQ:SANA	Sana Biotechnology Inc
2025/03/18	05:08	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:SANA	Sana Biotechnology Inc
2025/03/18	05:05	GlobeNewswire Inc.	Sana Biotechnology Reports Fourth Quarter and Full Year 2024 Financial Results and Business Updates	NASDAQ:SANA	Sana Biotechnology Inc
2025/03/15	05:18	Edgar (US Regulatory)	Form POSASR - Post-effective Amendment to an automatic shelf registration statement	NASDAQ:SANA	Sana Biotechnology Inc
2025/02/25	06:05	GlobeNewswire Inc.	Sana Biotechnology to Present at the Cowen 45th Annual Health Care Conference	NASDAQ:SANA	Sana Biotechnology Inc
2025/02/19	06:27	Edgar (US Regulatory)	Form 144 - Report of proposed sale of securities	NASDAQ:SANA	Sana Biotechnology Inc
2025/01/17	06:31	Edgar (US Regulatory)	Form 144 - Report of proposed sale of securities	NASDAQ:SANA	Sana Biotechnology Inc
2025/01/13	23:00	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:SANA	Sana Biotechnology Inc
2025/01/09	06:05	GlobeNewswire Inc.	Sana Biotechnology to Present at the 43rd Annual J.P. Morgan Healthcare Conference	NASDAQ:SANA	Sana Biotechnology Inc
2025/01/08	06:05	GlobeNewswire Inc.	Sana Biotechnology Announces Positive Clinical Results from Type 1 Diabetes Study of Islet Cell Transplantation Without Immunosuppression	NASDAQ:SANA	Sana Biotechnology Inc
2024/12/17	06:33	Edgar (US Regulatory)	Form 144 - Report of proposed sale of securities	NASDAQ:SANA	Sana Biotechnology Inc
2024/12/02	23:00	GlobeNewswire Inc.	Sana Biotechnology Announces Fast Track Designation for SC291 in Relapsed/Refractory Systemic Lupus Erythematosus	NASDAQ:SANA	Sana Biotechnology Inc
2024/11/27	08:20	Edgar (US Regulatory)	Form 144 - Report of proposed sale of securities	NASDAQ:SANA	Sana Biotechnology Inc
2024/11/26	07:40	Edgar (US Regulatory)	Form 144 - Report of proposed sale of securities	NASDAQ:SANA	Sana Biotechnology Inc
2024/11/26	06:05	GlobeNewswire Inc.	Sana Biotechnology to Present at December 2024 Investor Conferences	NASDAQ:SANA	Sana Biotechnology Inc
2024/11/08	23:14	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NASDAQ:SANA	Sana Biotechnology Inc
2024/11/08	23:07	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:SANA	Sana Biotechnology Inc
2024/11/08	23:00	GlobeNewswire Inc.	Sana Biotechnology Reports Third Quarter 2024 Financial Results and Business Updates	NASDAQ:SANA	Sana Biotechnology Inc
2024/11/05	06:30	GlobeNewswire Inc.	Sana Biotechnology Announces Increased Focus on Type 1 Diabetes and B-cell Mediated Autoimmune Diseases with the Potential to Deliver Clinical Proof of Concept Data Across Multiple Studies in 2024 and 2025	NASDAQ:SANA	Sana Biotechnology Inc
2024/10/23	21:00	PR Newswire (US)	Flagship Pioneering Announces Appointment of Junaid Bajwa as Senior Partner, Head of United Kingdom, and Science Partner for Pioneering Intelligence	NASDAQ:SANA	Sana Biotechnology Inc
2024/10/22	06:19	Edgar (US Regulatory)	Form 144 - Report of proposed sale of securities	NASDAQ:SANA	Sana Biotechnology Inc
2024/10/09	05:05	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:SANA	Sana Biotechnology Inc
2024/10/03	21:00	PR Newswire (US)	Invaio Sciences Appoints André Andonian as Chairman of the Board of Directors	NASDAQ:SANA	Sana Biotechnology Inc
2024/10/01	05:05	GlobeNewswire Inc.	Sana Biotechnology to Present at the Goldman Sachs Cell Therapy Day Conference	NASDAQ:SANA	Sana Biotechnology Inc
2024/09/13	05:36	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:SANA	Sana Biotechnology Inc
2024/08/30	05:05	GlobeNewswire Inc.	Sana Biotechnology to Present at September 2024 Investor Conferences	NASDAQ:SANA	Sana Biotechnology Inc
2024/08/27	05:05	GlobeNewswire Inc.	Sana Biotechnology Appoints Accomplished Drug Developer Dhaval Patel, M.D., Ph.D., as Executive Vice President and Chief Scientific Officer	NASDAQ:SANA	Sana Biotechnology Inc
2024/08/09	05:21	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NASDAQ:SANA	Sana Biotechnology Inc
2024/08/09	05:12	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:SANA	Sana Biotechnology Inc